{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:32:53Z","timestamp":1792513973402,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s11864-025-01307-7","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T07:31:58Z","timestamp":1741419118000},"page":"242-250","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Angiosarcoma: Role of Immunotherapy"],"prefix":"10.1007","volume":"26","author":[{"given":"Tom Wei-Wu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"key":"1307_CR1","doi-asserted-by":"crossref","unstructured":"Chen TW, Burns J, Jones RL, Huang PH. Optimal clinical management and the molecular biology of angiosarcomas. Cancers. 2020;12(11):3321.","DOI":"10.3390\/cancers12113321"},{"issue":"10","key":"1307_CR2","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1136\/jmedgenet-2019-106657","volume":"57","author":"E Shen","year":"2020","unstructured":"Shen E, Xiu J, Lopez GY, Bentley R, Jalali A, Heimberger AB, et al. POT1 mutation spectrum in tumour types commonly diagnosed among POT1-associated hereditary cancer syndrome families. J Med Genet. 2020;57(10):664\u201370.","journal-title":"J Med Genet"},{"issue":"18","key":"1307_CR3","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1016\/j.ejca.2014.10.004","volume":"50","author":"RJ Young","year":"2014","unstructured":"Young RJ, Natukunda A, Litiere S, Woll PJ, Wardelmann E, van der Graaf WT. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials. Eur J Cancer. 2014;50(18):3178\u201386.","journal-title":"Eur J Cancer"},{"issue":"32","key":"1307_CR4","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.1200\/JCO.2008.17.3146","volume":"26","author":"N Penel","year":"2008","unstructured":"Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008;26(32):5269\u201374.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1307_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s40425-019-0689-7","volume":"7","author":"V Florou","year":"2019","unstructured":"Florou V, Rosenberg AE, Wieder E, Komanduri KV, Kolonias D, Uduman M, et al. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J Immunother Cancer. 2019;7(1):213.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"1307_CR6","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","volume":"18","author":"HA Tawbi","year":"2017","unstructured":"Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493\u2013501.","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"1307_CR7","doi-asserted-by":"publisher","first-page":"11513","DOI":"10.1200\/JCO.2024.42.16_suppl.11513","volume":"42","author":"S van Ravensteijn","year":"2024","unstructured":"van Ravensteijn S, De Haan JJ, Gelderblom H, Hillebrandt-Roeffen MHS, de Voer RM, Speetjens FM, et al. Cemiplimab in locally advanced and\/or metastatic secondary angiosarcomas (CEMangio): A phase II clinical trial. J Clin Oncol. 2024;42(16_suppl):11513.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1307_CR8","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","volume":"19","author":"SP D'Angelo","year":"2018","unstructured":"D\u2019Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018;19(3):416\u201326.","journal-title":"Lancet Oncol"},{"key":"1307_CR9","doi-asserted-by":"crossref","unstructured":"Wagner MJ, Othus M, Patel SP, Ryan C, Sangal A, Powers B, et al. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). J Immunother Cancer. 2021;9(8):e002990.","DOI":"10.1136\/jitc-2021-002990"},{"issue":"9","key":"1307_CR10","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/S1470-2045(22)00392-8","volume":"23","author":"N Somaiah","year":"2022","unstructured":"Somaiah N, Conley AP, Parra ER, Lin H, Amini B, Solis Soto L, et al. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet Oncol. 2022;23(9):1156\u201366.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1307_CR11","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2303383","volume":"389","author":"AP Chen","year":"2023","unstructured":"Chen AP, Sharon E, O\u2019Sullivan-Coyne G, Moore N, Foster JC, Hu JS, et al. Atezolizumab for advanced alveolar soft part sarcoma. N Engl J Med. 2023;389(10):911\u201321.","journal-title":"N Engl J Med"},{"key":"1307_CR12","doi-asserted-by":"crossref","unstructured":"Wilky BA, Schwartz GK, Gordon MS, El-Khoueiry AB, Bullock AJ, Henick B, et al. Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with relapsed\/refractory metastatic sarcomas. J Clin Oncol. 2025;JCO2402524.","DOI":"10.1200\/JCO-24-02524"},{"issue":"3","key":"1307_CR13","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1001\/jamaoncol.2019.6152","volume":"6","author":"CM Kelly","year":"2020","unstructured":"Kelly CM, Antonescu CR, Bowler T, Munhoz R, Chi P, Dickson MA, et al. Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab: a phase 2 clinical trial. JAMA Oncol. 2020;6(3):402\u20138.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1307_CR14","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1038\/s41467-022-30874-8","volume":"13","author":"SP D'Angelo","year":"2022","unstructured":"D\u2019Angelo SP, Richards AL, Conley AP, Woo HJ, Dickson MA, Gounder M, et al. Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma. Nat Commun. 2022;13(1):3477.","journal-title":"Nat Commun"},{"issue":"5","key":"1307_CR15","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","volume":"15","author":"KA Khan","year":"2018","unstructured":"Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol. 2018;15(5):310\u201324.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"1307_CR16","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41571-024-00886-y","volume":"21","author":"HY Kuo","year":"2024","unstructured":"Kuo HY, Khan KA, Kerbel RS. Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials. Nat Rev Clin Oncol. 2024;21(6):468\u201382.","journal-title":"Nat Rev Clin Oncol"},{"issue":"16","key":"1307_CR17","doi-asserted-by":"publisher","first-page":"11503","DOI":"10.1200\/JCO.2023.41.16_suppl.11503","volume":"41","author":"JE Grilley-Olson","year":"2023","unstructured":"Grilley-Olson JE, Allred JB, Schuetze S, Davis EJ, Wagner MJ, Poklepovic AS, et al. A multicenter phase II study of cabozantinib plus nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902). J Clin Oncol. 2023;41(16):11503.","journal-title":"J Clin Oncol"},{"issue":"9829","key":"1307_CR18","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WT van der Graaf","year":"2012","unstructured":"van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England). 2012;379(9829):1879\u201386.","journal-title":"Lancet (London, England)"},{"issue":"5","key":"1307_CR19","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.clgc.2021.04.007","volume":"19","author":"S Chowdhury","year":"2021","unstructured":"Chowdhury S, Infante JR, Hawkins R, Voss MH, Perini R, Arkenau T, et al. A phase I\/II study to assess the safety and efficacy of pazopanib and pembrolizumab combination therapy in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2021;19(5):434\u201346.","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"1307_CR20","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41467-024-44875-2","volume":"15","author":"HJ Cho","year":"2024","unstructured":"Cho HJ, Yun KH, Shin SJ, Lee YH, Kim SH, Baek W, et al. Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial. Nat Commun. 2024;15(1):685.","journal-title":"Nat Commun"},{"key":"1307_CR21","doi-asserted-by":"crossref","unstructured":"Martin-Broto J, Hindi N, Grignani G, Martinez-Trufero J, Redondo A, Valverde C, et al. Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib\/II trial. J Immunother Cancer. 2020;8(2):e001561.","DOI":"10.1136\/jitc-2020-001561"},{"key":"1307_CR22","doi-asserted-by":"publisher","first-page":"S1034","DOI":"10.1016\/j.annonc.2023.09.1151","volume":"34","author":"NH Mu\u00f1iz","year":"2023","unstructured":"Mu\u00f1iz NH, Trufero JM, Grignani G, Garcia AS, Strauss S, Stacchiotti S, et al. 1922P Immunosarc II master trial: phase II of sunitinib and nivolumab in vascular sarcomas cohort - A GEIS, ISG and UCL study. Ann Oncol. 2023;34:S1034.","journal-title":"Ann Oncol"},{"issue":"24","key":"1307_CR23","doi-asserted-by":"publisher","first-page":"5612","DOI":"10.1158\/1078-0432.CCR-24-2519","volume":"30","author":"S Movva","year":"2024","unstructured":"Movva S, Seier K, Avutu V, Banks LB, Chan J, Chi P, et al. Histology-specific clinical trial of lenvatinib and pembrolizumab in patients with sarcoma. Clin Cancer Res. 2024;30(24):5612\u20139.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1307_CR24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","volume":"23","author":"G Kroemer","year":"2022","unstructured":"Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23(4):487\u2013500.","journal-title":"Nat Immunol"},{"issue":"16_suppl","key":"1307_CR25","doi-asserted-by":"publisher","first-page":"11512","DOI":"10.1200\/JCO.2024.42.16_suppl.11512","volume":"42","author":"HR Kim","year":"2024","unstructured":"Kim HR, Kim M, Kim JE, Kim H, Kim YJ, Kang MJ, et al. Phase II trial, multicenter, first line paclitaxel-avelumab treatment for inoperable angiosarcoma. J Clin Oncol. 2024;42(16_suppl):11512.","journal-title":"J Clin Oncol"},{"issue":"16","key":"1307_CR26","doi-asserted-by":"publisher","first-page":"11514","DOI":"10.1200\/JCO.2024.42.16_suppl.11514","volume":"42","author":"JE Grilley-Olson","year":"2024","unstructured":"Grilley-Olson JE, Allred JB, Schuetze S, Davis EJ, Poklepovic AS, Wagner MJ, et al. Alliance A091902: A multicenter randomized phase II trial of paclitaxel (P) with or without nivolumab (N) in patients (pts) with advanced angiosarcoma (AS). J Clin Oncol. 2024;42(16):11514.","journal-title":"J Clin Oncol"},{"key":"1307_CR27","first-page":"187","volume":"6","author":"L Bezu","year":"2015","unstructured":"Bezu L, Gomes-de-Silva LC, Dewitte H, Breckpot K, Fucikova J, Spisek R, et al. Combinatorial strategies for the induction of immunogenic cell death. Front Immunol. 2015;6:187.","journal-title":"Front Immunol"},{"issue":"23","key":"1307_CR28","doi-asserted-by":"publisher","first-page":"6424","DOI":"10.1158\/1078-0432.CCR-21-2001","volume":"27","author":"MB Livingston","year":"2021","unstructured":"Livingston MB, Jagosky MH, Robinson MM, Ahrens WA, Benbow JH, Farhangfar CJ, et al. Phase II study of pembrolizumab in combination with doxorubicin in metastatic and unresectable soft-tissue sarcoma. Clin Cancer Res. 2021;27(23):6424\u201331.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1307_CR29","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1001\/jamaoncol.2020.3689","volume":"6","author":"SM Pollack","year":"2020","unstructured":"Pollack SM, Redman MW, Baker KK, Wagner MJ, Schroeder BA, Loggers ET, et al. Assessment of doxorubicin and pembrolizumab in patients with advanced anthracycline-naive sarcoma: a phase 1\/2 nonrandomized clinical trial. JAMA Oncol. 2020;6(11):1778\u201382.","journal-title":"JAMA Oncol"},{"issue":"16","key":"1307_CR30","doi-asserted-by":"publisher","first-page":"11501","DOI":"10.1200\/JCO.2023.41.16_suppl.11501","volume":"41","author":"BA Wilky","year":"2023","unstructured":"Wilky BA, Maleddu A, Mailhot A, Cartwright C, Gao D, Tellez CM, et al. A single-arm, open-label phase 2 trial of doxorubicin plus zalifrelimab, a CTLA-4 inhibitor, with balstilimab, a PD-1 inhibitor, in patients with advanced\/metastatic soft tissue sarcomas. J Clin Oncol. 2023;41(16):11501.","journal-title":"J Clin Oncol"},{"key":"1307_CR31","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ctrv.2018.08.008","volume":"70","author":"J Cortes","year":"2018","unstructured":"Cortes J, Schoffski P, Littlefield BA. Multiple modes of action of eribulin mesylate: Emerging data and clinical implications. Cancer Treat Rev. 2018;70:190\u20138.","journal-title":"Cancer Treat Rev"},{"issue":"15","key":"1307_CR32","doi-asserted-by":"publisher","first-page":"3982","DOI":"10.1158\/0008-5472.CAN-16-3292","volume":"77","author":"A Dongre","year":"2017","unstructured":"Dongre A, Rashidian M, Reinhardt F, Bagnato A, Keckesova Z, Ploegh HL, et al. Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Can Res. 2017;77(15):3982\u20139.","journal-title":"Can Res"},{"issue":"7","key":"1307_CR33","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1158\/1078-0432.CCR-23-2250","volume":"30","author":"CL Haddox","year":"2024","unstructured":"Haddox CL, Nathenson MJ, Mazzola E, Lin JR, Baginska J, Nau A, et al. Phase II study of eribulin plus pembrolizumab in metastatic soft-tissue sarcomas: clinical outcomes and biological correlates. Clin Cancer Res. 2024;30(7):1281\u201392.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1307_CR34","doi-asserted-by":"publisher","first-page":"5135","DOI":"10.3390\/curroncol30050388","volume":"30","author":"R Lobrano","year":"2023","unstructured":"Lobrano R, Paliogiannis P, Zinellu A, Palmieri G, Persico I, Mangoni AA, et al. PD-L1 expression in cutaneous angiosarcomas: a systematic review with meta-analysis. Curr Oncol. 2023;30(5):5135\u201344.","journal-title":"Curr Oncol"},{"issue":"2","key":"1307_CR35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s12026-021-09259-4","volume":"70","author":"T Tomassen","year":"2022","unstructured":"Tomassen T, Weidema ME, Hillebrandt-Roeffen MHS, van der Horst C, group* P, Desar IME, et al. Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups. Immunol Res. 2022;70(2):256\u201368.","journal-title":"Immunol Res"},{"issue":"10","key":"1307_CR36","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1002\/ijc.28581","volume":"134","author":"H Fujii","year":"2014","unstructured":"Fujii H, Arakawa A, Utsumi D, Sumiyoshi S, Yamamoto Y, Kitoh A, et al. CD8(+) tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma. Int J Cancer. 2014;134(10):2393\u2013402.","journal-title":"Int J Cancer"},{"issue":"1","key":"1307_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41698-021-00150-x","volume":"5","author":"JY Chan","year":"2021","unstructured":"Chan JY, Tan GF, Yeong J, Ong CW, Ng DYX, Lee E, et al. Clinical implications of systemic and local immune responses in human angiosarcoma. NPJ Precis Oncol. 2021;5(1):11.","journal-title":"NPJ Precis Oncol"},{"key":"1307_CR38","doi-asserted-by":"crossref","unstructured":"van Ravensteijn SG, Versleijen-Jonkers YMH, Hillebrandt-Roeffen MHS, Weidema ME, Nederkoorn MJL, Bol KF, et al. Immunological and genomic analysis reveals clinically relevant distinctions between angiosarcoma subgroups. Cancers. 2022;14(23):5938.","DOI":"10.3390\/cancers14235938"},{"key":"1307_CR39","doi-asserted-by":"crossref","unstructured":"Rosenbaum E, Antonescu CR, Smith S, Bradic M, Kashani D, Richards AL, et al. Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center. J Immunother Cancer. 2022;10(4):e004149.","DOI":"10.1136\/jitc-2021-004149"},{"issue":"11","key":"1307_CR40","doi-asserted-by":"publisher","first-page":"5833","DOI":"10.1172\/JCI139080","volume":"130","author":"JY Chan","year":"2020","unstructured":"Chan JY, Lim JQ, Yeong J, Ravi V, Guan P, Boot A, et al. Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma. J Clin Investig. 2020;130(11):5833\u201346.","journal-title":"J Clin Investig"},{"issue":"2","key":"1307_CR41","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41591-019-0749-z","volume":"26","author":"CA Painter","year":"2020","unstructured":"Painter CA, Jain E, Tomson BN, Dunphy M, Stoddard RE, Thomas BS, et al. The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Nat Med. 2020;26(2):181\u20137.","journal-title":"Nat Med"},{"key":"1307_CR42","doi-asserted-by":"crossref","unstructured":"Espejo-Freire AP, Elliott A, Rosenberg A, Costa PA, Barreto-Coelho P, Jonczak E, et al. Genomic landscape of angiosarcoma: a targeted and immunotherapy biomarker analysis. Cancers. 2021;13(19):4816.","DOI":"10.3390\/cancers13194816"},{"issue":"2","key":"1307_CR43","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/path.6072","volume":"260","author":"SC Huang","year":"2023","unstructured":"Huang SC, Chang IY, Chang CJ, Liu H, Chen KH, Liu TT, et al. Association between hepatic angiosarcoma and end-stage renal disease: nationwide population-based evidence and enriched mutational signature of aristolochic acid exposure. J Pathol. 2023;260(2):165\u201376.","journal-title":"J Pathol"},{"key":"1307_CR44","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","volume":"27","author":"J Yu","year":"2021","unstructured":"Yu J, Green MD, Li S, Sun Y, Journey SN, Choi JE, et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med. 2021;27:152\u201364.","journal-title":"Nat Med"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01307-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01307-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01307-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T05:45:11Z","timestamp":1744350311000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01307-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1307"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01307-7","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,8]]},"assertion":[{"value":"24 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}